title: Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
abstract: Treatment with rosiglitazone has been associated with severe paradoxical HDL-c reductions. To our knowledge, there are very few reports of this reaction occurring when patients are treated without the combination of a fibrate. A case of severe HDL-c lowering in a patient treated with rosiglitazone without a fibrate is presented. The patient has been treated at a private practice clinic in southern Brazil. A 64-year-old woman with a 2-year history of type 2 diabetes mellitus was referred to her endocrinologist in June 2008. Rosiglitazone 4 mg q.d. was prescribed. Nine months later, the patient experienced a 90.90% decrease of her HDL-c levels. Rosiglitazone was withdrawn and the HDL-c returned to baseline. This paradoxical HDL-c reduction is a potentially severe adverse event. Patients prescribed rosiglitazone should have their HDL-c levels measured before and during therapy.
authors.affiliation: Instituto do Coração da Serra Gaúcha, Caxias do Sul, RS, Brazil.
authors.forename: Ricardo Luiz de
authors.initials: RL
authors.lastname: Almeida
authors.forename: Paulo
authors.initials: P
authors.lastname: Fedrizzi
authors.forename: Daniela
authors.initials: D
authors.lastname: Fedrizzi
authors.forename: Tobias Skrebsky de
authors.initials: TS
authors.lastname: Almeida
mesh_terms: D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
chemical_list: D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone